米国の体外受精機器市場の評価：製品タイプ別、手順タイプ別、エンドユーザー別、地域別、機会および予測、2018～2032年

米国の体外受精機器市場は、2025～2032年の予測期間中にCAGR 4.41％を記録し、2024年の60億7,000万米ドルから2032年には85億7,000万米ドルに成長すると予測されています。

米国の体外受精市場は、効率的なソリューションに対する需要の高まりと相まって、高度な技術やインフラが利用可能になったため、大きく成長しました。同国の市場拡大を後押ししている主な要因のひとつは、座りがちなライフスタイルや環境条件の変化により、国民の多くが生殖機能を低下させていることです。生殖医療にまつわるタブーは今や解消されつつあり、国民にその認識が広まるにつれて、人々はより自由に生殖医療を利用するようになっています。さらに、規制や保険による支援、ヘルスケア・インフラへの投資、テクノロジーの進歩、最先端ソリューションへの需要の高まりといった形で、政府が市場の成長軌道を後押ししています。

例えば、米国FertilityとOvation Fertilityは2023年4月に提携を発表し、米国で最も有名な不妊治療機関となります。アクセシビリティ、患者満足度、健康アウトカムを改善するために業界のベストプラクティスを適用することにより、この提携は革新と成長を促進しようとしています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 米国の体外受精機器市場の見通し、2018年～2032年

• 市場規模の分析と予測
  • 金額別
• 市場シェア分析と予測
  • 製品タイプ別
    • 装置
    • 試薬と培地
    • ソフトウェアとサービス
  • 手順タイプ別
    • 新鮮ドナーによる体外受精
    • 新鮮な非ドナー体外受精
    • 凍結ドナー体外受精
    • 凍結非ドナー体外受精
    • 自然周期体外受精
    • その他
  • エンドユーザー別
    • 不妊治療クリニック
    • 病院
    • 調査機関および学術センター
    • クライオバンク
  • 地域別
    • 北東部
    • 中西部
    • 西部
    • 南部
  • 市場シェア分析（上位5社およびその他- 金額別、2024年）、企業別
• 市場マップ分析、2024年
  • 製品タイプ別
  • 手順タイプ別
  • エンドユーザー別
  • 地域別

第5章 需要供給分析

第6章 バリューチェーン分析

第7章 ポーターのファイブフォース分析

第8章 PESTLE分析

第9章 価格分析

第10章 市場力学

• 市場促進要因
• 市場の課題

第11章 市場の動向と発展

第12章 規制枠組みとイノベーション

• 特許情勢
• 規制当局の承認
• イノベーション/新興技術

第13章 ケーススタディ

第14章 競合情勢

• 市場リーダー上位5社の競合マトリックス
• 上位5社のSWOT分析
• 市場上位10社の主要企業の情勢
  • Becton, Dickinson and Company
  • 会社概要
  • 主要経営陣
  • 製品とサービス
  • 財務状況（報告通り）
  • 主な市場フォーカスと地理的プレゼンス
  • 最近の動向/コラボレーション/ パートナーシップ/合併と買収
  • CooperSurgical, Inc.
  • Thermo Fisher Scientific Inc.
  • Irvine Scientific Inc.
  • MilliporeSigma（Merck KGaA）
  • Vitrolife Inc.
  • Eppendorf North America, Inc.
  • Leica Biosystems, Inc.
  • Hamilton Company
  • Origio USA, Inc.

上記の企業は市場シェアに基づいて注文を保留しておらず、調査作業中に入手可能な情報に基づいて変更される可能性があります。

第15章 戦略的提言

第16章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States In-vitro Fertilization Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States In-vitro Fertilization Market Share (%), By Product Type, 2018-2032F
• Figure 3. United States In-vitro Fertilization Market Share (%), By Procedure Type, 2018-2032F
• Figure 4. United States In-vitro Fertilization Market Share (%), By End-user, 2018-2032F
• Figure 5. United States In-vitro Fertilization Market Share (%), By Region, 2018-2032F
• Figure 6. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 7. By Procedure Type Size Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

United States in-vitro fertilization instruments market is projected to witness a CAGR of 4.41% during the forecast period 2025-2032, growing from USD 6.07 billion in 2024 to USD 8.57 billion in 2032.

The United States market for in-vitro fertilization has grown significantly because of the availability of advanced techniques and infrastructure coupled with the growing demand for efficient solutions. One of the primary factors propelling market expansions in the country is most of the population's declining reproductive health as a result of sedentary lifestyles and shifting environmental conditions. The taboo which is still associated with it is now dissolving and people are more freely availing these medical options as awareness spreads more around the country. Furthermore, the market's growth trajectory is being reinforced by the government in the form of regulatory and insurance support and the investments they make in healthcare infrastructure, advancements in technology, and the growing demand for cutting-edge solutions.

For example, U.S. Fertility & Ovation Fertility announced a partnership arrangement in April 2023 to become the most well-known fertility organization in the United States. By applying industry best practices to improve accessibility, patient satisfaction, and health outcomes, the alliance seeks to spur innovation and growth.

Technological Advancements in In-Vitro Fertilization Instruments Boosts Market Growth

Reproductive technology advancements have transformed IVF procedures in the US, increasing success rates and simplifying treatment plans. Clinics are now able to maximize embryo viability and minimize treatment cycles due to recent innovations such as AI-driven embryo selection tools, enhanced time-lapse imaging, and sophisticated cryopreservation methods such as vitrification. By increasing the likelihood of a successful pregnancy, these improvements boost professional efficiency and patient confidence.

For instance, in May 2023, Genea Biomedx Pty Ltd (a subsidiary of Genea Group) and AIVF Ltd. came together in a partnership to launch an integrated solution for personalized IVF care at a low cost. The integrated suite was built based on the Geri time-lapse incubator of Genea Biomedx and the EMA AI platform of AIVF.

According to reports, this technology improves embryo selection results by more than 25% when compared to traditional approaches by using deep-learning algorithms to evaluate embryo quality with previously unheard-of accuracy. Such advancements in technology not only demonstrate the revolutionary effects of digital health solutions in IVF but also highlight the market's dedication to further advancements in reproductive care. The US IVF market is expanding significantly because of the integration of these advancements, which improves treatment accessibility and efficacy.

Rising Infertility Rates and Changing Demographics Expedite the country's In-Vitro Fertilization Instruments Market Growth

Infertility rates in the United States are on the rise, primarily because of environmental causes, lifestyle-related health problems, and postponed childbirth. The need for assisted reproductive technologies, especially IVF, has increased as more people decide to have children later in life. Epidemiological statistics from 2023 suggested a considerable increase in infertility among women over 35, prompting both public awareness and aggressive fertility planning.

For example, Reproductive Health Partners, a well-known fertility centre in California, reported a 15% increase in IVF treatment cycles year over year in June 2023. This pattern is consistent with a larger demographic shift in which socioeconomic considerations and career-oriented lives cause people to put off family planning, which increases the need for medical intervention to conceive. As patients and healthcare professionals increasingly see IVF as a practical and occasionally required solution to age-related and lifestyle-induced fertility issues, the combination of rising infertility rates and changing societal standards has produced a favorable environment for market expansion.

Enhanced Regulatory and Insurance Support Fuel the US In-Vitro Fertilization Instruments Market Growth

Government policies and private insurance reforms in the United States have played a pivotal role in broadening access to IVF treatments. Increased regulatory support, along with mandates for better insurance coverage of fertility services, has lowered financial barriers, encouraging more couples to consider IVF.

In 2023, New York State enacted updated healthcare regulations that expanded insurance coverage for fertility treatments, including IVF, ensuring more patients could afford these procedures. Building on this momentum, in February 2024, a major private insurer, Blue Cross Blue Shield Association, announced a nationwide expansion of its fertility benefits program. This initiative significantly reduced out-of-pocket expenses for patients and spurred additional investments by clinics in advanced IVF technologies. Such regulatory and insurance advancements not only alleviate the financial burden on prospective parents but also stimulate market growth by increasing treatment accessibility. This supportive ecosystem is critical in driving demand and ensuring sustained growth in the competitive US IVF landscape.

Future Market Scenario (2025-2032F)

Many factors claim the growth of the United States in-vitro fertilization instruments market. Technological advancements give faster and more accurate results leading us to early diagnosis. Opportunity also lies in the increasing number of fertility concerns that the population is facing today. Promising initiatives of our government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial.

For instance, in January 2024, IVIRMA Global SL, a global medical institution acquired Eugin Group's North American Operations, which included the Boston IVF fertility network and Toronto-based TRIO. The plan is to ensure the success of many patients while offering evidence-based fertility options.

Key Players Landscape and Outlook

Key players in the United States in-vitro fertilization industry leverage strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For instance, Ovation Fertility and US Fertility merged in May 2023 to build a fertility platform that provides IVF and advanced fertility care in the United States.

Boston IVF and Cryoport, Inc. signed a three-year supply chain solutions agreement in April 2023 to facilitate the shipping of reproductive materials around the United States.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. United States In-vitro Fertilization Instruments Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product Type
    • 4.2.1.1. Equipment
      • 4.2.1.1.1. Incubators
      • 4.2.1.1.2. Cryosystems
      • 4.2.1.1.3. Imaging Systems
      • 4.2.1.1.4. Ovum Aspiration Pumps
      • 4.2.1.1.5. Micromanipulators
      • 4.2.1.1.6. Sperm Separation Systems
      • 4.2.1.1.7. Others
    • 4.2.1.2. Reagents and Media
      • 4.2.1.2.1. Embryo Culture Media
      • 4.2.1.2.2. Cryopreservation Media
      • 4.2.1.2.3. Sperm Processing Media
      • 4.2.1.2.4. Others
    • 4.2.1.3. Software and Services
  • 4.2.2. By Procedure Type
    • 4.2.2.1. Fresh Donor IVF
    • 4.2.2.2. Fresh Non-Donor IVF
    • 4.2.2.3. Frozen Donor IVF
    • 4.2.2.4. Frozen Non-Donor IVF
    • 4.2.2.5. Natural Cycle IVF
    • 4.2.2.6. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Fertility Clinics
    • 4.2.3.2. Hospitals
    • 4.2.3.3. Research Institutes and Academic Centers
    • 4.2.3.4. Cryobanks
  • 4.2.4. By Region
    • 4.2.4.1. Northeast
    • 4.2.4.2. Midwest
    • 4.2.4.3. West
    • 4.2.4.4. South
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Product Type
  • 4.3.2. By Procedure Type
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Patent Landscape
• 12.2. Regulatory Approvals
• 12.3. Innovations/Emerging Technologies

13. Case Studies

14. Competitive Landscape

• 14.1. Competition Matrix of Top 5 Market Leaders
• 14.2. SWOT Analysis for Top 5 Players
• 14.3. Key Players Landscape for Top 10 Market Players
  • 14.3.1. Becton, Dickinson and Company
    • 14.3.1.1. Company Details
    • 14.3.1.2. Key Management Personnel
    • 14.3.1.3. Products and Services
    • 14.3.1.4. Financials (As Reported)
    • 14.3.1.5. Key Market Focus and Geographical Presence
    • 14.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 14.3.2. CooperSurgical, Inc.
  • 14.3.3. Thermo Fisher Scientific Inc.
  • 14.3.4. Irvine Scientific Inc.
  • 14.3.5. MilliporeSigma (Merck KGaA)
  • 14.3.6. Vitrolife Inc.
  • 14.3.7. Eppendorf North America, Inc.
  • 14.3.8. Leica Biosystems, Inc.
  • 14.3.9. Hamilton Company
  • 14.3.10. Origio USA, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us and Disclaimer